Syk kinase inhibitor - BayerAlternative Names: Syk tyrosine kinase inhibitor - Bayer
Latest Information Update: 17 Dec 2003
At a glance
- Originator Bayer
- Mechanism of Action Syk kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 17 Dec 2003 No development reported - Preclinical for Asthma in Europe (unspecified route)
- 17 Jul 2001 Preclinical development for Asthma in Europe (Unknown route)